Skip to content
News Center
About Us Careers News Center Contact Us Legal Doing Business with Illumina Investors Illumina for Startups Customer Engagement Center

Complex disease genomics, Genetic & rare diseases, Corporate

Video: Professor Emma Baple on bringing whole-genome sequencing into clinical research

At ESHG, the Exeter professor discusses her genomics career and talks about the future of whole-genome sequencing

Professor Emma Baple on bringing whole-genome sequencing into clinical research
18 June 2026

At the European Society Human Genetics 2026 conference in Gothenburg, Sweden, more than 6000 global leaders across research, healthcare, and industry came together to discuss the latest advances in genomic medicine.

The meeting highlighted rapid progress and innovation in sequencing technologies and the growing integration of genomic insights into clinical practice. Speakers shared their real-world experiences implementing genomics at scale.

In the video below, Illumina customer Professor Emma Baple, reflects on the benefits of whole-genome sequencing. As a professor of Genomic Medicine at the University of Exeter and medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children, she also shares her perspective on how genomic medicine could evolve to improve outcomes for critically ill patients.

Also at the show, Illumina presented a poster, “TruPath™ Genome delivers a comprehensive human genome from a broad range of DNA inputs.” It examines how whole-genome sequencing performs across diverse, real-world sample types. The work highlights that, despite variability in collection methods, DNA quality, and workflows, genome coverage remains robust and highly usable. These findings underscore an important shift toward making genomics more resilient and accessible in everyday research settings.
Previous Article

Recent articles

What is proteomics? A simple guide to understanding measuring proteins at scale
What is proteomics? A simple guide to understanding measuring proteins at scale
When sequencing isn’t enough: A global forum for finding answers
When sequencing isn’t enough: A global forum for finding answers
8 Cancer organizations receive grants to expand access to genomic testing
8 Cancer organizations receive grants to expand access to genomic testing
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.